Jennifer Bath, Ph.D.

Chief Executive Officer and President

Jennifer holds a Ph.D. in Cellular and Molecular biology from North Dakota State University, and a Bachelor’s degree in Biology, with an emphasis on human genetics, from the University of Kansas. She began her career in academia, and moved into industry after a 15-year appointment as an Associate Professor of Cellular and Molecular Biology at Concordia College, Moorhead, Minnesota. She was the Founder and Executive Director of the Concordia College Global Vaccine Institute; whose mission is to prevent and treat neglected tropical diseases. Jennifer has broad experience in vaccine and therapeutic design, development and testing.

Dr. Bath served many guidance roles in industry including advising on the Economic Development Corporation’s Strategic Planning Initiatives, consulting biotechnology and pharmaceutical companies on strategic and operational business practices, and providing governance for workshops in technology entrepreneurship. She has established relationships with leaders in the fields of therapeutics and vaccinology, enhancing collaborative developments and partnerships in discovery.

Jennifer served in an executive role at Aldevron, LLC, as the Global Director of Client Relations, where she held both strategic and technical roles. She headed the global sales and client relations teams, and defined business strategies by applying knowledge based on the science, technology and the market. In addition, she served as a key technical specialist, particularly for therapeutic antibody discovery, and was responsible for retention and growth of the existing client base through individual efforts and efforts of the management team to deliver profitable, quality services.

Robert Beecroft

Chief Technical Officer and Director

Robert Beecroft is the founder and Chief Technical Officer of ImmunoPrecise and previously served as its Chief Executive Officer and President. Mr. Beecroft has over 25 years’ experience in the development of innovative and proprietary methods for the production of monoclonal and polyclonal antibodies and peptides. Mr. Beecroft has a B.Sc. in Microbiology from University of Victoria and has been involved in over 15 Research Projects over the course of the last 25 years and been an instructor for graduate students at the University of Victoria on the use and production of monoclonal antibodies for over 13 years.  In 2015, Mr. Beecroft was the recipient of the UVic Distinguished Alumni Award for the Faculty of Science, in recognition for being the Founder of ImmunoPrecise Antibodies Ltd.

Reg Beniac

Chief Operating Officer

As the COO of ImmunoPrecise Antibodies, Reg Beniac is responsible for running all facets of business operations including onboarding new acquisitions into the IPA family of companies. Reg works closely with the individual business unit leaders and teams to ensure that each unit continues to deliver outstanding service to a larger customer base. He has a proven executive management track record and over 20 years of international experience leading teams in the design, build and implementation business operations, sales, accounting, and financial systems. Reg’s experience includes key management consulting and business building roles at the Business Development Bank of Canada and his own company as well as being the key architect in the design and implementation a US Banking and Capital Markets regulatory compliance management system. Reg is an Adjunct Lecturer at the Gustavson School of Business (University of Victoria, Victoria British Columbia) and a graduate supervisor for the Smith School of Business (Queen’s University, Kingston Ontario). Reg earned a degree in Economics from the University of Victoria, an MBA from the Smith School of Business as well as is a Chartered Professional Accountant.

Deanna Dryhurst

Chief Scientific Officer

Dr. Dryhurst has been with ImmunoPrecise since 2010. She received an NSERC Industrial Research and Development Postdoctoral Fellowship to work on a platform for rabbit monoclonal antibody development at ImmunoPrecise Antibodies. Rabbit monoclonal antibodies are now a key part of what ImmunoPrecise provides to its clients. She is currently in charge of R&D at ImmunoPrecise where she is responsible for prioritization of research projects, alignment with corporate strategy and developing new product introductions. She received her B.Sc. in Biology, and her Ph.D. in Biochemistry and Molecular Biology from the University of Victoria.

Teri Otto

Vice President, Marketing and Sales Support

Teri Otto joined ImmunoPrecise in 1997 as a co-op student and continued as a fulltime employee upon graduation in 2000. She began as a technician and animal care manager. She has been a key part of developing ImmunoPrecise’s successful laboratory operations and antibody engineering capabilities, particularly in the area of mouse hybridomas. Ms. Otto holds a B.Sc. (with distinction) from University of Victoria in Microbiology and Associate Degrees in Psychology, Bio Chemistry, and Applied Chemistry from Camosum College in Victoria, BC.

Kevin Wong

Vice President of Corporate Services

Dr. Kevin Wong has served as President of ImmunoPrecise and Vice President of Corporate Services since joining the company in 2013. Dr. Wong has previous experience working in both industry and academic settings. He managed the laboratory operations for Protox Therapeutics for nine years prior to joining ImmunoPrecise. Dr. Wong spent six years at Cambridge University as a Research Associate in both the Departments of Biochemistry and Pathology, as well as two years as a Research Associate at University of Ottawa Department of Cellular and Molecular Medicine. Dr. Wong graduated from the University of Victoria with a Ph.D. in Biochemistry. Dr. Wong has been published in more than a dozen peer-reviewed articles in journals of biological sciences.